Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Miragen Therapeutics Inc (MGEN) USD 0.01

Sell:$0.79 Buy:$0.80 Change: $0.0406 (4.89%)
NASDAQ:2.83%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.79
Buy:$0.80
Change: $0.0406 (4.89%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.79
Buy:$0.80
Change: $0.0406 (4.89%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155 (miR-155), which is found at abnormally high levels in several blood cancers. The Company's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is involved in discovering and developing a pipeline of pre-clinical product candidates. Its pre-clinical product candidates include MRG-107 and MRG-110.

Contact details

Address:
6200 Lookout Rd
BOULDER
80301-3319
United States
Telephone:
+1 (303) 5315952
Website:
www.miragen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MGEN
ISIN:
US60463E1038
Market cap:
$38.36 million
Shares in issue:
46.18 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Jeffrey Hatfield
    Independent Chairman of the Board
  • William Marshall
    President, Chief Executive Officer, Director
  • Jason Leverone
    Chief Financial Officer, Treasurer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.